• Alias: LY231514; MTA
    • An inhibitor of TS, DHFR, GARFT, and AICARFT, the enzymes involved in folate metabolism and DNA synthesis, resulting in the inhibition of purine and thymidine nucleotide and protein synthesis.
    • FDA approved for unresectable, malignant mesothelioma in combination with cisplatin and metastatic or locally advanced, nonsquamous NSCLC; off-label use for metastatic bladder cancer, recurrent cervical cancer, platinum-resistant ovarian cancer, and metastatic thymoma.
    • Recommended dose: 500 mg/m2 IV over 10 minutes every 21 days. NOTE: Start vitamin supplements with folic acid and Vitamin B12 7 days prior to O b.i.d. for 3 days, starting 24 hours before pemetrexed dose
    Other topics in Targeted and Immunotherapy Agents